TIGIT (+PD-L1) blockade induces numerous complete responses (CR) in vivo, even against chemotherapy-resistant neuroblastoma, highlighting TIGIT blockade as promising immunotherapy for neuroblastoma. The gene discussed is TIGIT; the disease is neuroblastoma.